Immune adjuvants are immune modulators that have been developed in the context of infectious vaccinations.There is currently a growing interest in immune adjuvants due to the development of immunotherapy against cance...Immune adjuvants are immune modulators that have been developed in the context of infectious vaccinations.There is currently a growing interest in immune adjuvants due to the development of immunotherapy against cancers.Immune adjuvant mechanisms of action are focused on the initiation and amplification of the inflammatory response leading to the innate immune response,followed by the adaptive immune response.The main activity lies in the support of antigen presentation and the maturation and functions of dendritic cells.Most immune adjuvants are associated with a vaccine or incorporated into the new generation of m RNA vaccines.Few immune adjuvants are used as drugs.Hydroxyapatite(HA)ceramics and azoximer bromide(AZB)are overlooked molecules that were used in early clinical trials,which demonstrated clinical efficacy and excellent tolerance profiles.HA combined in an autologous vaccine was previously developed in the veterinary field for use in canine spontaneous lymphomas.AZB,an original immune modulator derived from a class of heterochain aliphatic polyamines that is licensed in Russia,the Commonwealth of Independent States,and Slovakia for infectious and inflammatory diseases,is and now being developed for use in cancer with promising results.These two immune adjuvants can be combined in various immunotherapy strategies.展开更多
Sugar-dependent targeting and immune adjuvant effects of hyperbranched glycosylated polypeptide nanoparticles were disclosed for ovalbumin(OVA)delivery system.The mannose-coated polypeptide nanoparticles can induce st...Sugar-dependent targeting and immune adjuvant effects of hyperbranched glycosylated polypeptide nanoparticles were disclosed for ovalbumin(OVA)delivery system.The mannose-coated polypeptide nanoparticles can induce strongest targeting and immune adjuvant effects to macrophages than those glucose/lactose-coated ones,which effectively transported OVA into cells and facilitated OVA subcellular escape from endolysosomes into cytoplasm with the assistance of UV irradiation or intracellular acidic pH.展开更多
The development of a safe and effective adjuvant that amplifies the immune response to an antigen is important for vaccine delivery. In this study, we developed pristine mesoporous carbon hollow spheres as high-capaci...The development of a safe and effective adjuvant that amplifies the immune response to an antigen is important for vaccine delivery. In this study, we developed pristine mesoporous carbon hollow spheres as high-capacity vaccine protein nanocarriers and safe adjuvants for boosting the immune response. Mono-dispersed invaginated mesostructured hollow carbon spheres （IMHCSs） have an average particle size of -200 nm, large pore size of 15 rim, and high pore volume of 2.85 cmB.g-1. IMHCSs exhibited a very high loading capacity （1,040 ~tg-mg-1） towards ovalbumin （OVA, a model antigen）, controlled OVA release behavior, excellent safety profile to normal cells, and high antigen delivery efficacy towards macrophages. In vivo immunization studies in mice demonstrated that OVA-loaded IMHCSs induced a 3-fold higher IgG response compared to a traditional adjuvant QuilA used in veterinary vaccine research. OVA delivered by IMHCSs induced a higher IgG1 concentration than IgG2a, indicating a T-helper 2 （Th2）-polarized response. Interferon-y and interleukin-4 concentration analysis revealed both T-helper 1 （Thl） and Th2 immune responses induced by OVA- loaded IMHCSs. IMHCSs are safer adjuvants than QuilA. Our study revealed that pure IMHCSs without further functionalization can be used as a safe adjuvant for promoting Th2-biased immune responses for vaccine delivery.展开更多
文摘Immune adjuvants are immune modulators that have been developed in the context of infectious vaccinations.There is currently a growing interest in immune adjuvants due to the development of immunotherapy against cancers.Immune adjuvant mechanisms of action are focused on the initiation and amplification of the inflammatory response leading to the innate immune response,followed by the adaptive immune response.The main activity lies in the support of antigen presentation and the maturation and functions of dendritic cells.Most immune adjuvants are associated with a vaccine or incorporated into the new generation of m RNA vaccines.Few immune adjuvants are used as drugs.Hydroxyapatite(HA)ceramics and azoximer bromide(AZB)are overlooked molecules that were used in early clinical trials,which demonstrated clinical efficacy and excellent tolerance profiles.HA combined in an autologous vaccine was previously developed in the veterinary field for use in canine spontaneous lymphomas.AZB,an original immune modulator derived from a class of heterochain aliphatic polyamines that is licensed in Russia,the Commonwealth of Independent States,and Slovakia for infectious and inflammatory diseases,is and now being developed for use in cancer with promising results.These two immune adjuvants can be combined in various immunotherapy strategies.
基金the financial support of the National Natural Science Foundation of China(Nos.22075176 and21774074)。
文摘Sugar-dependent targeting and immune adjuvant effects of hyperbranched glycosylated polypeptide nanoparticles were disclosed for ovalbumin(OVA)delivery system.The mannose-coated polypeptide nanoparticles can induce strongest targeting and immune adjuvant effects to macrophages than those glucose/lactose-coated ones,which effectively transported OVA into cells and facilitated OVA subcellular escape from endolysosomes into cytoplasm with the assistance of UV irradiation or intracellular acidic pH.
文摘The development of a safe and effective adjuvant that amplifies the immune response to an antigen is important for vaccine delivery. In this study, we developed pristine mesoporous carbon hollow spheres as high-capacity vaccine protein nanocarriers and safe adjuvants for boosting the immune response. Mono-dispersed invaginated mesostructured hollow carbon spheres （IMHCSs） have an average particle size of -200 nm, large pore size of 15 rim, and high pore volume of 2.85 cmB.g-1. IMHCSs exhibited a very high loading capacity （1,040 ~tg-mg-1） towards ovalbumin （OVA, a model antigen）, controlled OVA release behavior, excellent safety profile to normal cells, and high antigen delivery efficacy towards macrophages. In vivo immunization studies in mice demonstrated that OVA-loaded IMHCSs induced a 3-fold higher IgG response compared to a traditional adjuvant QuilA used in veterinary vaccine research. OVA delivered by IMHCSs induced a higher IgG1 concentration than IgG2a, indicating a T-helper 2 （Th2）-polarized response. Interferon-y and interleukin-4 concentration analysis revealed both T-helper 1 （Thl） and Th2 immune responses induced by OVA- loaded IMHCSs. IMHCSs are safer adjuvants than QuilA. Our study revealed that pure IMHCSs without further functionalization can be used as a safe adjuvant for promoting Th2-biased immune responses for vaccine delivery.
